Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials.

Abstract

Most clinical trials evaluating COVID-19 therapeutics include assessments of antiviral activity. In recently completed outpatient trials, changes in nasal SARS-CoV-2 RNA levels from baseline were commonly assessed using analysis of covariance (ANCOVA) or mixed models for repeated measures (MMRM) with single-imputation for results below assay lower limits of quantification (LLoQ). Analyzing changes in viral RNA levels with singly-imputed values can lead to biased estimates of treatment effects. In this paper, using an illustrative example from the ACTIV-2 trial, we highlight potential pitfalls of imputation when using ANCOVA or MMRM methods, and illustrate how these methods can be used when considering values <LLoQ as censored measurements. Best practices when analyzing quantitative viral RNA data should include details about the assay and its LLoQ, completeness summaries of viral RNA data, and outcomes among participants with baseline viral RNA ≥LLoQ, as well as those with viral RNA <LLoQ.

• Authors: Carlee B Moser, Kara W Chew, Mark J Giganti, Jonathan Z Li, Evgenia Aga, Justin Ritz, Alexander L Greninger, Arzhang Cyrus Javan, Eric S Daar, Judith S Currier, Joseph J Eron, Davey M Smith, Michael D Hughes
• Journal: medRxiv : the preprint server for health sciences (medRxiv) (Mar 17 2023) United States
• PMID: 36993419 (Publication Type: Preprint)